Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dow Stough

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Clinical and Aesthetic Dermatology|November 25, 2010
Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label studyDow Stough, Alicia D Bucko, George Vamvakias, et al.
Mayo Clinic Proceedings|October 11, 2005
Psychological effect, pathophysiology, and management of androgenetic alopecia in menDow Stough, Kurt Stenn, Robert Haber, et al.
Journal of the American Academy of Dermatology|November 18, 2006
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasterideElise A Olsen, Maria Hordinsky, David Whiting, et al.
Journal of the American Academy of Dermatology|April 25, 2020
Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatologyHarrison P Nguyen, Jonathan A Go, John S Barbieri, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Evaluation and treatment of male and female pattern hair lossElise A Olsen, Andrew G Messenger, Jerry Shapiro, et al.
Cutis|December 28, 2002
Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosisJoseph Jorizzo, Daniel Stewart, Alicia Bucko, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2011
A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitisJo Lynne Herzog, James A Solomon, Zoe Draelos, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Clinical and Aesthetic Dermatology|November 25, 2010
Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label studyDow Stough, Alicia D Bucko, George Vamvakias, et al.
Mayo Clinic Proceedings|October 11, 2005
Psychological effect, pathophysiology, and management of androgenetic alopecia in menDow Stough, Kurt Stenn, Robert Haber, et al.
Journal of the American Academy of Dermatology|November 18, 2006
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasterideElise A Olsen, Maria Hordinsky, David Whiting, et al.
Journal of the American Academy of Dermatology|April 25, 2020
Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatologyHarrison P Nguyen, Jonathan A Go, John S Barbieri, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Evaluation and treatment of male and female pattern hair lossElise A Olsen, Andrew G Messenger, Jerry Shapiro, et al.
Cutis|December 28, 2002
Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosisJoseph Jorizzo, Daniel Stewart, Alicia Bucko, et al.
Journal of Drugs in Dermatology : JDD|August 6, 2011
A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitisJo Lynne Herzog, James A Solomon, Zoe Draelos, et al.
Pageof 2